Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $34.4 million.

  • Applied Therapeutics' Liabilities and Shareholders Equity fell 6774.39% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.3 million, marking a year-over-year decrease of 5111.07%. This contributed to the annual value of $86.7 million for FY2024, which is 5810.0% up from last year.
  • According to the latest figures from Q3 2025, Applied Therapeutics' Liabilities and Shareholders Equity is $34.4 million, which was down 6774.39% from $37.3 million recorded in Q2 2025.
  • In the past 5 years, Applied Therapeutics' Liabilities and Shareholders Equity registered a high of $151.2 million during Q1 2024, and its lowest value of $30.0 million during Q1 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $54.8 million (2023), whereas its average is $70.4 million.
  • Per our database at Business Quant, Applied Therapeutics' Liabilities and Shareholders Equity skyrocketed by 40404.61% in 2024 and then crashed by 7077.59% in 2025.
  • Quarter analysis of 3 years shows Applied Therapeutics' Liabilities and Shareholders Equity stood at $54.8 million in 2023, then skyrocketed by 58.1% to $86.7 million in 2024, then plummeted by 60.35% to $34.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $34.4 million for Q3 2025, versus $37.3 million for Q2 2025 and $56.9 million for Q1 2025.